Bioventix reported revenues and adjusted pre-tax profits 1% and 2% above our forecasts, with adjusted EPS 7% above forecasts due to a lower estimated tax rate of 17%; driven by 9% revenue growth (10% for the continuing product/royalty base). Bioventix remains strongly cash generative, which drives a 90p (+22%) final dividend and full-year dividend of 152p. Troponin is now the 2nd largest contributor to revenues, rising 30% to £1.61m and showing 11% sequential 6-monthly growth; regaining its mome ....
